Utah Medical Products (NASDAQ:UTMD) CEO Purchases $66,750.00 in Stock

Utah Medical Products, Inc. (NASDAQ:UTMD) CEO Kevin Cornwell bought 1,000 shares of the company’s stock in a transaction dated Thursday, October 29th. The shares were purchased at an average price of $66.75 per share, with a total value of $66,750.00. Following the transaction, the chief executive officer owned 189,472 shares of the company’s stock, valued at $12,647,256. The trade was a 0.53% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Utah Medical Products Stock Up 1.9%

Shares of UTMD opened at $68.07 on Friday. Utah Medical Products, Inc. has a 12-month low of $53.66 and a 12-month high of $76.89. The firm has a market capitalization of $216.46 million, a PE ratio of 20.38 and a beta of 0.38. The stock’s fifty day simple moving average is $72.90 and its 200-day simple moving average is $68.01.

Utah Medical Products (NASDAQ:UTMD) last announced its quarterly earnings data on Thursday, October 22nd. The medical instruments supplier reported $0.88 EPS for the quarter. The firm had revenue of $8.62 million during the quarter. Utah Medical Products had a return on equity of 8.83% and a net margin of 30.48%.

Utah Medical Products Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, October 5th. Stockholders of record on Thursday, September 17th were paid a $0.31 dividend. This represents a $1.24 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend was Thursday, September 17th. Utah Medical Products’s dividend payout ratio (DPR) is 37.13%.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. State of Wyoming grew its stake in shares of Utah Medical Products by 39.1% during the third quarter. State of Wyoming now owns 6,683 shares of the medical instruments supplier’s stock worth $495,000 after purchasing an additional 1,880 shares during the period. Cardinal Capital Management increased its holdings in Utah Medical Products by 8.7% in the third quarter. Cardinal Capital Management now owns 29,458 shares of the medical instruments supplier’s stock valued at $2,190,000 after purchasing an additional 2,364 shares during the last quarter. Empowered Funds LLC acquired a new position in Utah Medical Products in the second quarter valued at about $225,000. Bank of America Corp DE acquired a new position in Utah Medical Products in the second quarter valued at about $283,000. Finally, Sanctuary Advisors LLC acquired a new position in Utah Medical Products in the second quarter valued at about $544,000. Institutional investors and hedge funds own 69.60% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Utah Medical Products from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 9th. One investment analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

About Utah Medical Products

Utah Medical Products, Inc (NASDAQ:UTMD) develops, manufactures and distributes medical devices used primarily in hospital and clinical settings. The company focuses on specialized products for women’s health, childbirth, neonatal care, electrosurgery, gastroenterology and related medical applications.

Its product portfolio includes fetal monitoring electrodes and catheters, intrauterine pressure monitoring devices, vacuum-assisted delivery systems, neonatal respiratory and care products, electrosurgical accessories, and other disposable and specialty medical instruments.